Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Fortress Biotech
FBIO
Fortress Biotech
Delayed Payer Approvals Will Curtail Revenues But Offer Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
16 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$4.00
42.8% undervalued
intrinsic discount
16 Aug
US$2.29
Loading
1Y
6.5%
7D
1.8%
Author's Valuation
US$4.0
42.8% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$4.0
42.8% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-104m
231m
2014
2017
2020
2023
2025
2026
2028
Revenue US$230.7m
Earnings US$37.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
33.46%
Biotech revenue growth rate
11.95%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.29%
Calculation
US$37.49m
Earnings '28
x
5.97x
PE Ratio '28
=
US$224.02m
Market Cap '28
US$224.02m
Market Cap '28
/
43.96m
No. shares '28
=
US$5.10
Share Price '28
US$5.10
Share Price '28
Discounted to 2025 @ 8.41% p.a.
=
US$4.00
Fair Value '25
